ImmunityBio (IBRX) Non-Current Deffered Revenue (2014 - 2018)

ImmunityBio (IBRX) has reported Non-Current Deffered Revenue for 5 consecutive years, with $2.7 million the latest figure, recorded in Q4 2018.

• In Q4 2018, Non-Current Deffered Revenue fell 17.62% year-over-year to $2.7 million; the TTM figure through Dec 2018 stood at $2.7 million (down 17.62% YoY), while the FY2018 annual figure was $2.7 million, down 17.62% from the prior year.
• Non-Current Deffered Revenue fell to $2.7 million in Q4 2018 per IBRX's latest filing, from $2.9 million in the prior quarter.
• Across five years, Non-Current Deffered Revenue topped out at $3.6 million in Q2 2017 and bottomed at $3000.0 in Q2 2015.
• Historically, Non-Current Deffered Revenue has averaged $1.7 million across 5 years, with a median of $1.6 million in 2015.
• On a YoY basis, Non-Current Deffered Revenue climbed as much as 6466.67% in 2016 and fell as far as 77.87% in 2016.
• ImmunityBio's Non-Current Deffered Revenue stood at $521000.0 in 2014, then soared by 62.19% to $845000.0 in 2015, then plunged by 77.87% to $187000.0 in 2016, then surged by 1678.07% to $3.3 million in 2017, then decreased by 17.62% to $2.7 million in 2018.
• Business Quant data shows IBRX's Non-Current Deffered Revenue at $2.7 million in Q4 2018, $2.9 million in Q3 2018, and $3.0 million in Q2 2018.